Literature DB >> 19679262

Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease.

Astrid Spruss1, Ina Bergheim.   

Abstract

Worldwide, not only the prevalence of obesity has increased dramatically throughout the last three decades but also the incidences of co-morbid conditions such as diabetes type 2 and liver disease have increased. The 'hepatic manifestation of the metabolic syndrome' is called nonalcoholic fatty liver disease (NAFLD) and comprises a wide spectrum of stages of liver disease ranging from simple steatosis to liver cirrhosis. NAFLD of different stages is found in approximately 30% of adults and approximately 20% in the US population. Not just a general overnutrition but also an elevated intake of certain macronutrients such as fat and carbohydrates and herein particularly fructose has been claimed to be risk factors for the development for NAFLD; however, the etiology of this disease is still unknown. The present review outlines some of the potential mechanisms associated with the development of NAFLD and fructose intake with a particular focus on the role of the intestinal barrier functions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19679262     DOI: 10.1016/j.jnutbio.2009.05.006

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  55 in total

Review 1.  [Comorbidity oriented oncology - an overview].

Authors:  Ralph Simanek; Michael Wuensch; Roland Edlinger; Bernhard Hammerl-Ferrari; Ludwig Kramer; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

Review 2.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Authors:  Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

3.  Dietary Carbohydrate Modifies the Inverse Association Between Saturated Fat Intake and Cholesterol on Very Low-Density Lipoproteins.

Authors:  A C Wood; E K Kabagambe; I B Borecki; H K Tiwari; J M Ordovas; D K Arnett
Journal:  Lipid Insights       Date:  2011-08-23

Review 4.  Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments.

Authors:  E Scorletti; P C Calder; C D Byrne
Journal:  Endocrine       Date:  2011-09-06       Impact factor: 3.633

Review 5.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.

Authors:  Jung Sub Lim; Michele Mietus-Snyder; Annie Valente; Jean-Marc Schwarz; Robert H Lustig
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

6.  Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

Authors:  Thuy-Anh Le; Rohit Loomba
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

Review 7.  Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.

Authors:  Zeinab Mokhtari; Deanna L Gibson; Azita Hekmatdoost
Journal:  Adv Nutr       Date:  2017-03-15       Impact factor: 8.701

8.  Chronic Alcohol Consumption Causes Liver Injury in High-Fructose-Fed Male Mice Through Enhanced Hepatic Inflammatory Response.

Authors:  Ming Song; Theresa Chen; Russell A Prough; Matthew C Cave; Craig J McClain
Journal:  Alcohol Clin Exp Res       Date:  2016-02-09       Impact factor: 3.455

9.  Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice.

Authors:  Valentina Volynets; Astrid Spruss; Giridhar Kanuri; Sabine Wagnerberger; Stephan C Bischoff; Ina Bergheim
Journal:  J Lipid Res       Date:  2010-09-16       Impact factor: 5.922

Review 10.  Possible links between intestinal permeability and food processing: A potential therapeutic niche for glutamine.

Authors:  Jean Robert Rapin; Nicolas Wiernsperger
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.